Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,004.00 by Analysts at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lowered by Truist Financial from $1,126.00 to $1,004.00 in a report released on Wednesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on REGN. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Citigroup initiated coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target for the company. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,044.48.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of REGN opened at $733.59 on Wednesday. The company has a market capitalization of $80.61 billion, a PE ratio of 18.15, a PEG ratio of 2.19 and a beta of 0.10. The stock’s 50-day moving average price is $756.46 and its two-hundred day moving average price is $966.75. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12 month low of $693.00 and a 12 month high of $1,211.20.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the last quarter. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Finally, Ashton Thomas Private Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $39,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.